MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Data provided by Kaleidoscope.
Events and Presentations
September 14, 2022 at 1:25 PM EDT
September 12, 2022 at 7:00 AM EDT
August 9, 2022 at 11:00 AM EDT